PRECISION PHENOTYPE — 2163615
Application number
2163615
International Registration Number
1641756
Type(s)
Standard Characters
Category
Trademark
CIPO Status
ABANDONED SECTION 36
TM5 status
DEAD/APPLICATION/
Withdrawn/Abandoned
The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.
Filed
2021-05-25
International Registration
2021-05-25
Applicant
Neumora Therapeutics, Inc.
8000 Marina Blvd, Suite 700
Brisbane CA 94005
UNITED STATES OF AMERICA
Agent
SMART & BIGGAR LP
SCOTIA PLAZA
40 KING STREET WEST
40th FLOOR
TORONTO
ONTARIO M5H3Y2
Documents
Index headings
- PRECISION PHENOTYPE
- PHENO TYPE
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders.
Services (Nice class & Statement)
- 42
- (1) Research and development of pharmaceutical preparations and substances for the treatment, management and prevention of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders; scientific research, namely, analyzing genetic, genomic, biological and clinical data; scientific research, namely, analyzing genetic, genomic, biological and clinical data for research and development relating to the treatment of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders via targeted drug therapies.
- 44
- (2) Medical analysis services relating to the treatment of patients, namely, analyzing genetic, genomic, biological and clinical data; medical analysis services relating to the treatment of patients, namely, analyzing genetic, genomic, biological and clinical data for the development and treatment of neurological diseases and disorders, psychiatric diseases and disorders, central nervous system conditions, brain disorders and sleep disorders via targeted drug therapies.
Claims
- Priority Filing Date: December 03, 2020, Country or Office: UNITED STATES OF AMERICA, Application No. 90356587 in association with the same kind of goods and in association with the same kind of services
Recordals (known also as Footnotes)
CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2022-03-30 DATE OF CHANGE / DATE DE CHANGEMENT: 2022-02-17 COMMENTS / COMMENTAIRES: From: RBNC THERAPEUTICS, INC. To: Neumora Therapeutics, Inc. CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2022-12-07 DATE OF CHANGE / DATE DE CHANGEMENT: 2022-11-11 COMMENTS / COMMENTAIRES: From: Neumora Therapeutics, Inc. To: Neumora Therapeutics, Inc.Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2021-05-25 | Registration | |
| International Registration | 2021-05-25 | 2031-05-25 | |
| Created | 2022-02-02 | ||
| Formalized | 2022-02-02 | ||
| Designation Notification - Madrid Protocol | 2022-02-03 | 2023-08-03 | |
| Agent Changed | 2022-02-18 | From/De: To/A: 2502 | |
| Amendment to Application | 2022-03-30 | From: RBNC THERAPEUTICS, INC. To: Neumora Therapeutics, Inc. | |
| Notification of Possible Opposition Sent | 2022-12-05 | ||
| Amendment to Application | 2022-12-08 | DP:2022-12-07 Effective Date: 2022-11-11 | |
| Search Recorded | 2023-05-16 | ||
| Examiner's First Report | 2023-05-16 | 2023-11-16 | |
| Total Provisional Refusal | 2023-05-16 | 2023-11-16 | |
| Default Notice Sent | 2023-12-04 | 2024-02-04 | |
| Abandoned - Section 36 | 2024-02-22 | ||
| Confirmation of Total Provisional Refusal Sent | 2024-02-22 |